Search results
Showing 1696 to 1710 of 2581 results for methods
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
Mental health of adults in contact with the criminal justice system (QS163)
This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.
View quality statements for QS163Show all sections
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Discontinued Reference number: GID-TA10026
Process guide for adoption support resources for health technologies (PMG23)
This process and methods guide has been withdrawn.
Discontinued Reference number: GID-TA10445